Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Celestica Inc (CLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Celestica Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $46, while Celestica Inc trades at $335.37 (market cap $39.16B). Which is the better fit depends on your goals.
| AMDY | CLS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $59.52 | $472.40 |
52-Week Low | $29.80 | $181.34 |
Market Cap | — | $39.16B |
Enterprise Value | — | $39.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CLS trades at $327.15, up 3.99% in 24 hours, with a bearish technical signal but strong fundamentals including a 52.69% ROE and Q2 2026 EPS of $2.54 beating estimates. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, though this may cause near-term dilution.
The outlook is positive with analyst consensus at Buy (64.29%) and a $466.50 price target, driven by AI demand and partnerships. Risks include equity dilution and premium valuation, but growth catalysts from hyperscaler investments support long-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Celestica Inc
Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.
Read more on CLS →
